You are here: Industry Insights > Novartis

News List

Novartis CEO says Malaria drug is biggest hope against coronavirus – SonntagsZeitung expresspharma
March 31, 2020
Other companies including Bayer and Teva have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing its experimental drug remdesivir against coronavirus.
Novartis partners with life sciences companies to fight Covid-19 pharmaceutical-technology
March 30, 2020
Novartis has partnered with a consortium of life sciences companies to rapidly develop, produce and deliver vaccines, diagnostics and treatments for Covid-19 coronavirus infection.
Novartis, Life Sciences Companies Commit Assets to COVID-19 Pandemic with Bill & Melinda Gates Foundation americanpharmaceuticalreview
March 27, 2020
Novartis and a consortium of life sciences companies announced a collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic.
Five-year Zolgensma data shows SMA benefit pharmatimes
March 25, 2020
Novartis has released new Zolgensma (onasemnogene abeparvovec-xioi) data, demonstrating rapid, significant and clinically meaningful therapeutic benefit of the drug in patients with spinal muscular atrophy (SMA).
Novartis publishes more positive data for Zolgensma pharmaceutical-technology
March 25, 2020
Novartis subsidiary AveXis presented positive, updated data from three clinical trials of its one-dose gene therapy for spinal muscular atrophy (SMA), Zolgensma.
Novartis to Donate Up to 130 Million Doses of Hydroxychloroquine americanpharmaceuticalreview
March 24, 2020
Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response.
Novartis, Amneal, Apotex offer hydroxychloroquine for Covid-19 pharmaceutical-technology
March 24, 2020
Novartis is set to donate up to 130 million doses of generic hydroxychloroquine to help fight the Covid-19 coronavirus infection that led to a global pandemic.
Novartis Receives Approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma americanpharmaceuticalreview
March 23, 2020
Novartis Pharma announced the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Zolgensma® (onasemnogene abeparvovec).
Novartis Recalls Sandimmune, Neoral Blister Packs Due to Packaging Failure contractpharma
March 20, 2020
Corrective action plan to address blister packs that do not meet U.S. child-resistant packaging requirements, there are no quality or efficacy issues.
Novartis gets Japan’s approval for Zolgensma pharmaceutical-technology
March 20, 2020
Novartis Pharma has received the Japanese Ministry of Health, Labour and Welfare (MHLW) approval for Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page